Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Stopped Study was suspended pending renovation and reopening of the facility manufacturing the study product, and the study was ultimately terminated in February of 2026.
Conditions
- Acute Leukemia
- Myelodysplastic Syndromes
Interventions
- DRUG: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Sponsor
Edwin Horwitz
Collaborators